No Data
Theratechnologies Resubmits SBLA For F8 Formulation Of Tesamorelin; Decision Expected By March 2025
Theratechnologies Brief: Submitting Updated Tesamorelin F8 Formulation SBLA for FDA Review
Theratechnologies Submits Updated Tesamorelin F8 Formulation SBLA for FDA Review
Theratechnologies Inc. (TSE:TH) Has Found A Path To Profitability
Express News | Foghorn Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People With HIV
No Data